From the Research
Spasmiona can be used in patients with G6PD deficiency, but with caution and careful monitoring for signs of hemolysis, as the current evidence does not list dicyclomine among high-risk medications for G6PD deficiency 1, 2, 3. When considering the use of Spasmiona in patients with G6PD deficiency, it is essential to weigh the potential benefits against the risks. The primary concern with G6PD deficiency is the potential for oxidative stress, which can lead to hemolysis. However, according to the most recent and highest quality study, many medications previously thought to be risky for G6PD-deficient patients have been prescribed safely 1.
- Key points to consider:
- Dicyclomine, the active ingredient in Spasmiona, is not typically listed among high-risk medications for G6PD deficiency 2, 3.
- Individual responses to medications can vary, and careful monitoring is recommended 1, 2, 3.
- If prescribed, start with the lowest effective dose, typically 10-20 mg three to four times daily, and monitor for signs of hemolysis such as fatigue, jaundice, or dark urine.
- Consider alternative antispasmodics with better-established safety profiles in G6PD deficiency if the patient shows any adverse reactions or if their G6PD deficiency is severe. The most recent study from 2024 provides reassurance that many medications can be used safely in G6PD-deficient patients, but it is crucial to prioritize caution and monitoring to minimize the risk of hemolysis 1.